Postgraduate Institute for Medicine, in Partnership with RMEI Medical Education, Announces an Educational Awareness Campaign for World Arthritis Day
Postgraduate Institute for Medicine (PIM) and RMEI Medical Education (RMEI) have launched the first in a three-part series of global medical education interventions to address ongoing gaps in clinical practice, and to raise awareness for World Arthritis Day by focusing on the importance of early diagnosis and access to evidence-based treatment in rheumatoid arthritis (RA). The partners hope the first activity will stimulate professional reflection on practice behavior and patient outcomes, while later content will address emerging data on therapeutic pathways and patient engagement.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171012005711/en/
The series is entitled Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes, and will incorporate alternating cycles of education, assessment, and recalibration of content to meet evolving healthcare provider needs.
“If pharmacological treatment for rheumatoid arthritis is started within 12 weeks after the onset of symptoms, this could minimize the level of joint impact over time and increase the chances of remission1,” noted Dr. Jeffrey Curtis, professor of medicine and director of the Arthritis Clinical Intervention Program at the University of Alabama at Birmingham, in the United States. “Both EULAR and ACR guidelines advocate for a treat-to-target approach with shared decision making. There has been a general failure to adopt this in clinical practice, and the weight of the evidence is that these approaches work to optimize care for patients with RA.”
Each of the 3 online courses will present learners with unique educational environments: the first, called Clinical Reflections™, uses a virtual clinical setting to allow learners to rethink decisions based on realistic patient care scenarios and to modify their management plans accordingly to affect behavioral change. The second, Clinical Convergence ®, engages learners by integrating video patient perspectives with clinical content to illustrate potential differences between clinician and patient perceptions of their care. The third and final course, Clinical Conversations™, teaches clinicians certain technical skills and a step-wise process for integrating shared decision-making into patient care, a core competency not taught extensively in medical school and not appropriately utilized by clinicians in various specialties and disciplines.
Supported by independent educational grant funding from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals, this advanced analytics-driven initiative is the first of its kind in the RA education field.
“Why this is important to patients with RA might seem obvious, since clinicians who engage in RA-related education tailored to specific drivers of educational need tend to improve the care they deliver to their patients,” said Jacqui Brooks, MBBCh, MRCPsych, Senior Vice President of Medical Strategy at RMEI. “Our research has shown that proactive monitoring of disease activity and selecting appropriate treatment options – particularly in patients with moderate to severe disease – as well as use of shared decision-making approaches, are areas of particular deficit. The Learner Pathway in RA will address these issues with laser-like focus.”
This initiative has been planned to support EULAR’s “Don’t Delay, Connect Today” campaign, an initiative for uniting the voices of People with Arthritis and Rheumatism (PARE) organizations, scientific member societies, and health professional associations, with the united goal of highlighting the importance of early diagnosis and access to treatment.
About RMEI Medical Education
Founded in 1990, RMEI Medical Education (RMEI) is one of the longest operating medical education companies in the US. With an emphasis on sophisticated learner analytics for program design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. In designing innovative teaching modalities such as the Clinical Convergence™ platform for its 5 primary therapeutic areas, RMEI seeks to inspire greater collaboration within the care team and stronger commitment to patient engagement. For more information, visit www.rmei.com, call 856-672-3152, or e-mail at email@example.com.
The European League Against Rheumatism (EULAR) is a pan-European, non-profit organization that represents people with arthritis/rheumatism, health professionals in rheumatology, and scientific societies of rheumatology across Europe. EULAR aims to reduce the burden of rheumatic and musculoskeletal diseases (RMDs) on the individual and society and to improve the treatment, prevention, and rehabilitation of them. It promotes the translation of research advances into improved daily care for people with RMDs, and fights for governing bodies in Europe to recognize the needs of people with RMDs.
EULAR’s members include scientific societies, health professional associations, patient organizations, corporate members and people with RMDs across Europe. 2017 marks the 70th anniversary of EULAR, marking 70 years of research and the collaboration between physicians, health professionals, and patients. For more information, please visit www.eular.org.
1 Van der Linden MP, le Cessie S, Raza K, et al. Long-Term Impact of Delay in Assessment of Patients with Early Arthritis. Arthritis Rheum. 2010;62(12):3537-3546.
RMEI Medical Education
Dave Clausen, CHCP, 856-672-3152
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD20.5.2018 21:15 | Pressemelding
ResMed (NYSE: RMD, ASX: RMD) announced today the results of two clinical analyses conducted for the U.K. and U.S., demonstrating the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation (NIV) therapy for patients with persistent hypercapnia following a life-threatening exacerbation of chronic obstructive pulmonary disease (COPD). The ResMed-backed Home Oxygen Therapy – Home Mechanical Ventilation (HOT-HMV) health economic studies, presented today at the ATS 2018 International Conference, build on earlier data demonstrating the clinical and cost effectiveness of HOT-HMV therapy (i.e. combining home oxygen therapy with home NIV), compared to treating with oxygen alone. The U.K. study found that HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmission. The U.S. analysis found a 58.3 percent reduction in 30-day readmissions for HOT-HMV patients compared to those on home oxygen alone – and that HOT-HMV can actually save patients money
WELL Building Standard Gaining Momentum in Europe18.5.2018 14:47 | Pressemelding
As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe. WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the pa
Utimaco Announces Intent to Acquire Atalla from Micro Focus18.5.2018 09:03 | Pressemelding
Utimaco, the global #2 in Hardware Security Modules (HSMs), today announced the intent to acquire the Atalla HSM and ESKM business lines from Micro Focus, which were previously owned by Hewlett Packard Enterprise (HPE) prior to the September 2017 merger of its Software business with Micro Focus. Germany-based Utimaco, active in the HSM market for over 35 years, is a global manufacturer of general purpose HSMs. Utimaco has built its market leading position focusing on indirect sales through OEM or channel business partners and selling its SecurityServer product line into industries as diverse as automotive, government, media & entertainment, smart metering, semiconductors, telecommunications and the banking and financial services sectors. Utimaco is traditionally strong in its German home market based on its longstanding German banking association certification (DK) and has recently achieved PCI accreditation for the SecurityServer product line. With the acquisition of Atalla, one of th
Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections18.5.2018 07:00 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson, today announced 21 company-sponsored abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5. New data analyses in support of a portfolio of products, including the investigational treatments erdafitinib and apalutamide, as well as approved treatments Imbruvica® (ibrutinib), Darzalex® (daratumumab), and Zytiga® (abiraterone acetate) will be highlighted across urothelial, haematologic and prostate cancers. Notably, Phase 2 trial results for the investigational compound erdafitinib, which received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation, will be presented during an oral presentation on Sunday, June 3 (Abstract #4503).1,2 For haematologic cancers, Phase 3 data from the iNNOVATE study will provide the first look at ibrutinib plus rituximab versus placebo plus rituximab in patients with newly diagnosed and relapsed/refractory Wald
Karisma Hotels & Resorts to Open Allure Palazzi Kotor Bay Hotel by Karisma in June 201818.5.2018 06:00 | Pressemelding
Karisma Hotels & Resorts, an award-winning luxury hotel collection which owns and manages properties in Latin America, the Caribbean and Europe, is pleased to announce the opening of Allure Palazzi Kotor Bay Hotel by Karisma in June 2018. Built from the ground up in Montenegro’s idyllic Dobrota, the exclusive five-star beachfront property seamlessly blends stunning architecture and design with its mountainous landscape, offering spellbinding views of Kotor Bay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006456/en/ Rendering of Allure Palazzi Kotor Bay (Photo: Business Wire) Sitting on Kotor Bay’s only private beach, the resort features 89 premium guestrooms, 10 villas with private beachfront access, and three breathtaking penthouse suites, each with a balcony or terrace. Allure Palazzi Kotor Bay’s accommodations encompass sumptuous bedding, divine amenities, and carefully selected color palettes bringing the sunny
Siemens Financial Services Selects GTC’s @GlobalTrade Platform for Management of Export Documentary Credits18.5.2018 04:00 | Pressemelding
GlobalTrade Corporation (GTC) has announced today that Siemens Financial Services (SFS) has selected its @GlobalTrade Multi-bank Trade Finance Platform for management of its export documentary credits. The platform will be initially rolled out in Germany and thereafter expanded to Siemens entities globally. The system will electronically aggregate all incoming documentary credits in a global database, facilitate review and approval, assist in preparation of compliant documents and enable faster presentation of documents electronically to advising and issuing banks. Gerhard Heubeck, Head of Trade Finance Advisory at Siemens Financial Services, reasons the need for the new system implementation as follows: "After many years of using one of the first standard IT systems available for export documentary credits, the time has come to find a successor tool capable to meet the new requirements such as multi-client capability, processing of new SWIFT message formats, global accessibility, and